The continuous increase in the costs of developing new drugs and medical devices drives increases in medical expenses. Seventy to ninety percent of these costs are associated with clinical trials. Therefore, the development of cost-effective methods to perform clinical trials remains a challenge. One approach is to use patient registries, collections of data related to patients with a specific diagnosis, condition, or procedure. Patient registries are used in Denmark, Sweden, and the USA for the enrollment of patients into clinical trials, and to evaluate endpoints. In Japan, a national project for registry-oriented clinical research, termed the 'Clinical Innovation Network' (CIN), was initiated in 2016. Here, we provide an overview of the CIN and discuss its impact on drug and device development in Japan.
机构:
Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Practices & Outcome, Stanford, CA 94305 USAStanford Univ, Sch Med, Stanford Prevent Res Ctr, Program Prevent Practices & Outcome, Stanford, CA 94305 USA
机构:
Keio Univ, Grad Sch Pharmaceut Sci, Div Drug Dev & Regulatory Sci, Minato Ku, Tokyo 1058512, Japan
Astellas Pharma Inc, Clin Dev Dept, Global Dev, Oncol,Chuo Ku, Tokyo 1038411, JapanKeio Univ, Grad Sch Pharmaceut Sci, Div Drug Dev & Regulatory Sci, Minato Ku, Tokyo 1058512, Japan
Maeda, Hideki
Kurokawa, Tatsuo
论文数: 0引用数: 0
h-index: 0
机构:
Keio Univ, Grad Sch Pharmaceut Sci, Div Drug Dev & Regulatory Sci, Minato Ku, Tokyo 1058512, JapanKeio Univ, Grad Sch Pharmaceut Sci, Div Drug Dev & Regulatory Sci, Minato Ku, Tokyo 1058512, Japan